Is It Time To Review The Vaccination Strategy To Protect Adults Against Invasive Pneumococcal Disease? CorcoranMary MereckieneJolita MurchanStephen McElligottMartha O’FlanaganD CotterSuzanne CunneyRobert HumphreysHilary 2019 <p>Pneumococcal conjugate vaccines (PCVs) have reduced the predominant serotypes causing invasive pneumococcal disease (IPD). We assessed the impact of the paediatric 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13) among older adults. We compared serotype-specific incidence rates from 2007/08 to 2016/17, expressed as incidence rate ratios (IRR). Introducing PCV7 and PCV13 into the childhood immunisation programme resulted in a decline in these serotypes in adults ≥65 years of age, with PCV7 serotypes decreasing by 85% (IRR=0.11, 95%CI: 0.05-0.22, p</p>